Metoclopramide Tablets Recalled Due to Cross Contamination

Key Takeaways:

• The US Food and Drug Administration (FDA) has issued a voluntary Class II recall for metoclopramide tablets, USP, 5 mg. The affected batch has been identified as Lot 3116509 (expires July 2027).
• The recall was initiated by Safecor Health, LLC due to cross contamination with other medications, a quality issue that is likely to cause temporary or medically reversible adverse health consequences or has a low probability of serious adverse health consequences.
• Metoclopramide is used to treat gastroparesis and gastroesophageal reflux disease (GERD).

The FDA has issued a Class II recall for metoclopramide tablets, USP, 5 mg. This product is being recalled by Safecor Health, LLC based in Rockford, Illinois. The recall was initiated on October 6, 2026, and received a Class II classification on October 23, 2026. A Class II classification means the use of this product is likely to cause temporary or medically reversible adverse health consequences or has a low probability of serious adverse health consequences.

The recall was initiated after the firm discovered other tablets co-mingled with the metoclopramide product. This issue affects Lot 3116509, which will expire in July 2027. Safecor Health sent out a public notice via email; no press release was issued for this recall.

Metoclopramide is used to treat gastroparesis in patients with diabetes. It is also used to relieve heartburn in patients with GERD. Pharmacists should identify and quarantine Lot 3116509, remove it from inventory, and coordinate with prescribers to provide an alternative supply.

Reference

FDA. Enforcement Report. November 4, 2026. Accessed November 4, 2026. https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=223263